@entity1276 and XXXX . Incidence, clinical picture, and treatment.

@entity1 @entity227 @entity3308 @entity3976 @entity1276 @entity1313 @entity5 @entity979 @entity1829 @entity2846 @entity2946
One may consider that the @entity1 with @entity1276 complicating a primary @entity1313 has two distinctly different diseases: 1) a @entity5 , and 2) @entity1276 . The @entity1276 may be obstructive, communicating, or (in the case of @entity2846 ) hypersecretory. This paper presents the incidence, symptomatology, and management of @entity1276 associated with @entity1313 in 156 @entity1 and with @entity979 in 21 @entity1 , all treated by the first author during the period 1967 to 1979. @entity2946 was the most commonly encountered @entity5 . Of 117 @entity1 with cerebellar-fourth @entity5 , 110 had @entity1276 , whereas 11 of 34 with @entity3308 and all 21 with @entity979 presented with @entity1276 . Of the total 143 @entity1 with @entity1276 , shunts were inserted before craniotomy in 123, with the interval between shunt insertion and craniotomy for @entity5 removal ranging from 1 to 21 days. Eighteen of these @entity1 required shunt revisions after craniotomy; 36 of 80 @entity1 followed for 6 months or more had their shunts permanently removed, but it was necessary to reinsert the shunt from 5 days to 13 months later in 30% of these @entity1 . Only 25 @entity1 remained permanently shunt-free. It is considered that the placement of shunts before craniotomy is justified by the extraordinarily high incidence of @entity1829 and @entity227 associated with @entity1276 . " @entity3976 " and dissemination of neoplastic cells through the shunting system are theoretical contraindications to precraniotomy shunt insertion, although the former is rare (3%), and there is no statistical evidence to support the latter.
